• China’s NMPA cleared an IND for SKB575/HBM7575, a long-acting bispecific antibody for asthma.
• The drug is co-developed by Kelun-Biotech, 6990.HK, with Harbour BioMed, 02142.HK.
• SKB575/HBM7575 targets TSLP plus an undisclosed second target; it is also in Phase I testing for atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95209) on July 15, 2026, and is solely responsible for the information contained therein.